Biomarkers in Cancer Detection, Diagnosis, and Prognosis

被引：122

作者：

Das, Sreyashi ^{[1
]}

Dey, Mohan Kumar ^{[1
]}

Devireddy, Ram ^{[1
]}

Gartia, Manas Ranjan ^{[1
]}

机构：

[1] Louisiana State Univ, Dept Mech & Ind Engn, Baton Rouge, LA 70803 USA

来源：

SENSORS | 2024年 / 24卷 / 01期

基金：

美国国家科学基金会;

关键词：

biomarkers; DNA; RNA; lipids; PET; MRI; CT needle biopsy; RNAseq; proteomics; CORE-NEEDLE-BIOPSY; CIRCULATING TUMOR-CELLS; POSITRON-EMISSION-TOMOGRAPHY; EPSTEIN-BARR-VIRUS; REGULATORY T-CELLS; CARCINOEMBRYONIC ANTIGEN CEA; NUCLEAR LAMIN EXPRESSION; GALECTIN-1; SERUM-LEVELS; PERIPHERAL LYMPH-NODES; NECK SQUAMOUS-CELL;

D O I：

10.3390/s24010037

中图分类号：

O65 [分析化学];

学科分类号：

070302 ; 081704 ;

摘要：

Biomarkers are vital in healthcare as they provide valuable insights into disease diagnosis, prognosis, treatment response, and personalized medicine. They serve as objective indicators, enabling early detection and intervention, leading to improved patient outcomes and reduced costs. Biomarkers also guide treatment decisions by predicting disease outcomes and facilitating individualized treatment plans. They play a role in monitoring disease progression, adjusting treatments, and detecting early signs of recurrence. Furthermore, biomarkers enhance drug development and clinical trials by identifying suitable patients and accelerating the approval process. In this review paper, we described a variety of biomarkers applicable for cancer detection and diagnosis, such as imaging-based diagnosis (CT, SPECT, MRI, and PET), blood-based biomarkers (proteins, genes, mRNA, and peptides), cell imaging-based diagnosis (needle biopsy and CTC), tissue imaging-based diagnosis (IHC), and genetic-based biomarkers (RNAseq, scRNAseq, and spatial transcriptomics).

引用

页数：55

共 423 条

[1]

Aarnio M, 1999, INT J CANCER, V81, P214, DOI 10.1002/(SICI)1097-0215(19990412)81:2<214::AID-IJC8>3.3.CO

[2]

2-C

[3] Circulating miR-483-3p and miR-21 is highly expressed in plasma of pancreatic cancer [J].